ATE354352T1 - Verfahren zur partikelherstellung - Google Patents

Verfahren zur partikelherstellung

Info

Publication number
ATE354352T1
ATE354352T1 AT02715546T AT02715546T ATE354352T1 AT E354352 T1 ATE354352 T1 AT E354352T1 AT 02715546 T AT02715546 T AT 02715546T AT 02715546 T AT02715546 T AT 02715546T AT E354352 T1 ATE354352 T1 AT E354352T1
Authority
AT
Austria
Prior art keywords
liquid
particles
temperature
substance
modulator
Prior art date
Application number
AT02715546T
Other languages
English (en)
Inventor
Goran Eric Sundholm
Mustafa Demirbuker
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE354352T1 publication Critical patent/ATE354352T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02715546T 2001-01-26 2002-01-22 Verfahren zur partikelherstellung ATE354352T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process

Publications (1)

Publication Number Publication Date
ATE354352T1 true ATE354352T1 (de) 2007-03-15

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715546T ATE354352T1 (de) 2001-01-26 2002-01-22 Verfahren zur partikelherstellung

Country Status (21)

Country Link
US (2) US7108867B2 (de)
EP (1) EP1357901B1 (de)
JP (1) JP4175892B2 (de)
KR (1) KR100853596B1 (de)
CN (1) CN1298312C (de)
AT (1) ATE354352T1 (de)
BR (1) BR0206439A (de)
CA (1) CA2433838A1 (de)
CY (1) CY1106550T1 (de)
DE (1) DE60218285T2 (de)
DK (1) DK1357901T3 (de)
ES (1) ES2281509T3 (de)
GB (1) GB0102075D0 (de)
IL (2) IL156720A0 (de)
MX (1) MXPA03006537A (de)
NO (1) NO20033241D0 (de)
NZ (1) NZ526942A (de)
PT (1) PT1357901E (de)
SI (1) SI1357901T1 (de)
WO (1) WO2002058674A2 (de)
ZA (1) ZA200304953B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
BR0317523A (pt) * 2002-12-19 2005-11-16 Baxter Int Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos
CN100434133C (zh) * 2003-04-29 2008-11-19 欧加农股份有限公司 反溶剂凝固方法
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
AU2004277419B2 (en) * 2003-09-30 2007-10-11 Brown University Research Foundation Nanoparticulate therapeutic biologically active agents
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
AU2008214319A1 (en) * 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
US8585943B2 (en) * 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6668652B2 (ja) 2015-09-18 2020-03-18 日本精工株式会社 直動案内装置、直動案内装置用エンドキャップ
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
MX2023014091A (es) * 2021-06-28 2023-12-11 Micro Motion Inc Medicion de fluidos no ideal por flujometro de coriolis y metodos relacionados.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062530T3 (es) 1989-05-01 1994-12-16 Alkermes Inc Procedimiento para producir particulas pequeñas de moleculas biologicamente activas.
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
ATE386506T1 (de) 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
AU3705799A (en) 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1425355A1 (de) * 2001-07-12 2004-06-09 Eastman Kodak Company Eine komprimierte flüssige zusammensetzung
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
NZ526942A (en) 2005-04-29
KR20030070921A (ko) 2003-09-02
JP2004521891A (ja) 2004-07-22
WO2002058674A3 (en) 2002-11-21
CN1487825A (zh) 2004-04-07
NO20033241L (no) 2003-07-17
MXPA03006537A (es) 2003-09-22
SI1357901T1 (sl) 2007-08-31
WO2002058674A2 (en) 2002-08-01
PT1357901E (pt) 2007-05-31
US20040058007A1 (en) 2004-03-25
HK1063157A1 (en) 2004-12-17
IL156720A0 (en) 2004-01-04
US7108867B2 (en) 2006-09-19
DK1357901T3 (da) 2007-06-04
AU2002225193B2 (en) 2006-07-27
IL156720A (en) 2010-03-28
DE60218285T2 (de) 2007-11-15
CY1106550T1 (el) 2012-01-25
KR100853596B1 (ko) 2008-08-22
ES2281509T3 (es) 2007-10-01
EP1357901B1 (de) 2007-02-21
CA2433838A1 (en) 2002-08-01
US20070009604A1 (en) 2007-01-11
ZA200304953B (en) 2004-08-25
JP4175892B2 (ja) 2008-11-05
NO20033241D0 (no) 2003-07-17
DE60218285D1 (de) 2007-04-05
US7829123B2 (en) 2010-11-09
GB0102075D0 (en) 2001-03-14
EP1357901A2 (de) 2003-11-05
BR0206439A (pt) 2003-12-30
CN1298312C (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
ATE354352T1 (de) Verfahren zur partikelherstellung
DE60131165D1 (de) Gel auf der basis von polysacchariden
EA200601957A1 (ru) Удаление загрязнителей из природного газа с помощью охлаждения
ATE295185T1 (de) Verfahren zur herstellung von sehr feinen teilchen bestehend aus einem wirtsmolekül mit inseriertem wirkstoff
ATE232754T1 (de) Verfahren und vorrichtung zur herstellung von partikeln
ATE426446T1 (de) Verfahren und vorrichtung zum strippen von ammoniak aus flussigkeiten
MY138064A (en) Method for the separation of acids from chemical reaction mixtures by means of ionic fluids
ATE488533T1 (de) Verfahren zur herstellung von modifiziertem polymer, vorrichtung zur herstellung von modifiziertem polymer und modifiziertes polymer
DE60210963D1 (de) Reagenz zur isolierung von rna
ATE349460T1 (de) Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE60030999D1 (de) Verfahren zur herstellung von teilchen
Adair et al. A soluble protein derived from elastin
ATE335750T1 (de) Verfahren zur herstellung von organosilylalkylpolysulfanen
DE602005016540D1 (de) Verfahren zur herstellung von mikrokugeln auf basis von ionisch vernetztem polysaccharid
Gallagher et al. Hydrolysis of casein: a comparative study of two proteases and their peptide maps
DE60118739D1 (de) Verfahren zur isolierung eines proteins
ATE412890T1 (de) Verfahren zur tensid-quantifizierung eines proteinpräparates
ATE318279T1 (de) Verfahren zur herstellung von organomodifizierten polysiloxanen unter verwendung ionischer flüssigkeiten
Iwata et al. Rabbit pulmonary angiotensin-converting enzyme: the NH2-terminal fragment with enzymatic activity and its formation from the native enzyme by NH4OH treatment
ATE551991T1 (de) Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
DE502007006511D1 (de) Verfahren zur herstellung von mikropartikeln
ATE455177T1 (de) Verfahren zur kontrolle zellulärer prozesse in pflanzen
ATE522604T1 (de) Verfahren zur herstellung von proteinen durch elektropulsierung
ATE288487T1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1357901

Country of ref document: EP

REN Ceased due to non-payment of the annual fee